Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- M3 Poised to More than Double Revenue from Clinical Trial Services
December 5, 2014
- Safety Confirmed in Preliminary Results from PI Study of Preventive AIDS Vaccine: Dnavec
December 4, 2014
- Astellas, Janssen to End JAK Inhibitor Licensing Agreement
December 3, 2014
- Nippon Shinyaku’s Selexipag Filed for European Approval
December 3, 2014
- Otsuka to Buy US Firm Avanir Pharmaceuticals to Fully Enter Neurology Market
December 3, 2014
- Takata Seiyaku Obtains Marketing Authorization Rights for Antihistamine Polaramine from MSD
December 3, 2014
- Kowa Launches Glanatec for Treatment of Glaucoma and Ocular Hypertension
December 3, 2014
- Xtandi Approved for Chemotherapy-Naïve Patients in Europe: Astellas
December 3, 2014
- Takeda’s Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by US FDA
December 3, 2014
- A-zas Looks to Offer E-Detailing App, Big-Data Analyses to More Firms
December 2, 2014
- Pralia Captures Top Spot in GP Market in October “Mind Share” Ranking
December 2, 2014
- Eisai Upgrades China to Independent Region with New Holding Firm
December 2, 2014
- Ferring to Launch Japan’s 1st Progestational Hormone Agent in ART Program on Dec. 5
December 2, 2014
- Eisai Files Lenvatinib for Approval in South Korea
December 2, 2014
- MTPC, Sawai Ink Final Pact on Transfer of Kashima Plant in April
December 2, 2014
- Daiichi Sankyo, UCB to Jointly Commercialize Epilepsy Drug Lacosamide
December 1, 2014
- Nippon Kayaku Rolls Out Remicade Biosimilar
December 1, 2014
- Novartis to Launch Stalevo Combination Tablets on Dec. 8
December 1, 2014
- Takeda to Transform Osaka Plant into Specialty Manufacturing Site for Leuplin
December 1, 2014
- Sandoz Launches Biosimilar of G-CSF Product Gran; Comarkets with Sawai
December 1, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…